ANO1 and cystic fibrosis: This proposed activity of TMEM16A has been used as one of the salient arguments to progress TMEM16A blockers as novel therapeutics to treat mucus hypersecretion in asthma and CF (Benedetto et al., 2019; Cabrita et al., 2019).